Pharming Group (NASDAQ:PHAR) Sees Significant Decrease in Short Interest

Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 5,300 shares, a drop of 29.3% from the January 31st total of 7,500 shares. Based on an average daily volume of 6,600 shares, the short-interest ratio is currently 0.8 days.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Jefferies Financial Group started coverage on Pharming Group in a report on Monday, December 9th. They issued a "buy" rating and a $14.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research report on Tuesday, December 17th.

Pharming Group Stock Down 4.9 %

Pharming Group stock traded down $0.44 during trading hours on Thursday, hitting $8.43. The company had a trading volume of 9,009 shares, compared to its average volume of 5,976. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $11.94. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The firm has a market capitalization of $573.16 million, a P/E ratio of -32.40 and a beta of -0.10. The firm's fifty day moving average is $9.21 and its 200-day moving average is $8.56.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company's stock.

Remove Ads

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.